Target intelligence / Profile preview

Ribosomal protein L17 pseudogene 3 (RPL17P3)

Target
RPL17P3
Molecular classification
Other (specifically, *processed pseudogene*)
01

Overview

Ribosomal protein L17 pseudogene 3 (RPL17P3) is a genomic sequence related to the ribosomal protein L17 gene (RPL17) that has lost its protein-coding ability through evolutionary processes, referred to as a processed pseudogene[8]. Pseudogenes like RPL17P3 typically arise by duplication or retrotransposition of a functional gene but acquire disabling mutations or lack necessary regulatory elements, rendering them non-functional for protein synthesis[8]. There are dozens of RPL17-related pseudogenes in the human genome, but none encode functional ribosomal protein or serve as therapeutic targets[8]. RPL17P3 represents a non-functional genomic remnant of the ribosomal protein L17 gene and has no role as a drug target, disease gene, or biomarker. No structured therapeutic data, drug interactions, or safety considerations are relevant for this entry.

Other names
RPL17P3
02

Mechanism of action

None (no actionable protein or mechanism; lacks translation and function)

03

Biological functions

None (no known protein-coding or biological functional activity; pseudogenes do not encode functional proteins)
04

Disease associations

None (no evidence as a direct disease gene; not associated with disease phenotypes)
05

Safety considerations

None (no functional activity as a complex macromolecule or protein to pose therapeutic challenges)
06

Interacting drugs

None (as a pseudogene, there are no drugs that interact with it)
07

Biomarkers

None (no indication in current literature of use as a clinical biomarker)

Beyond the preview

Go deeper on Ribosomal protein L17 pseudogene 3 (RPL17P3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L17 pseudogene 3 (RPL17P3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call